- Glitazones: discuss is not in the end2007 | Second Faculty of Medicine
- New findings from studies on glitazones2005 | Second Faculty of Medicine
- Possibilities of influencing B-cell function by glitazones2005 | Second Faculty of Medicine
- Glitazones, PROactive study, treatment of diabetes and prevention of cardiovascular complications +12005 | Second Faculty of Medicine
- Treatment of type 2 diabetes mellitus with oral antidiabetics. Part IV. - Thiazolidinedione (TZD) derivatives - glitazones2007 | Second Faculty of Medicine
- Glitazones and sulphonylurea in treatment with metformin in obese patients of type 22008 | Second Faculty of Medicine
- Effect of adding glitazone or sulphonylurea derivate in obese patients with type 2 diabetes mellitus treated by metformine2008 | Second Faculty of Medicine
- Current of glitazones in the treatment of metabolic syndrome type II2006 | First Faculty of Medicine
- Rosiglitazone in the treatment of diabetes in 2010, what’s new?2010 | First Faculty of Medicine
- AMPK blocker P5499 (Compound C) attenuates troglitazone effect on Beta3 adrenergic triggered NO production in primary culture of visceral adipocytes indicating that first 24 hours effect of glitazone is mainly AMPK mediated and not PPARgamma mediatedPublication without faculty affiliation
- The effect of newer antidiabetic drugs on the weight of patients with type 2 diabetes2010 | First Faculty of Medicine
- Dual blocking of PPAR receptors2006 | First Faculty of Medicine
- Ovlivnění kompenzace diabetu, lipidového profilu a antropometrických ukazatelů u obézních diabetiků s diabetickou dyslipidémií dlouhodobým podáváním glitazonůPublication without faculty affiliation
- Rosiglitazone - molecule of heaven or hell?2008 | Second Faculty of Medicine
- Rosiglitazone: Safe confirmation in 2008 year2008 | Second Faculty of Medicine
- Adipocytes as model for studying drug targets: the example of PPARgama and certain post receptor signalsPublication without faculty affiliation
- History of oral antidiabetic agents2011 | First Faculty of Medicine
- Duální stimulace receptorů PPAR: rizika a pochybnostiPublication without faculty affiliation
- Pioglitazone in the treatment of type 2 diabetes mellitus in the year 2017: Current insight into benefits and disadvantages of this medication2017 | First Faculty of Medicine
- New guidelines for management od type 2 DM2007 | Second Faculty of Medicine
- Sitagliptin2008 | Second Faculty of Medicine
- Diabetes mellitus and ischemic heart disease2009 | Second Faculty of Medicine
- The effect of rosiglitazone on the expression of thrombogenic markers on leukocytes in type 2 diabetes mellitus2009 | First Faculty of Medicine, Faculty of Science
- Treatment of type 2 diabetes mellitus with oral antidiabetics. Part 5 - Glinids (meglitinides), acarbose, incretins2009 | Second Faculty of Medicine
- Antihyperglycaemic treatment and vascular disease2010 | First Faculty of Medicine
- Oral antidiabetic drugs in treatment of type 1 diabetes mellitus2016 | Second Faculty of Medicine, Third Faculty of Medicine
- Ovlivnění kardiovaskulárního rizika perorálními antidiabetiky2019 | First Faculty of Medicine
- Metformin jako antidiabetikum první volby2020 | First Faculty of Medicine
- Diagnosis and treatment of Latent Autoimmune Diabetes in Adults in everyday clinical practice2020 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Physical Education and Sport